Purpose: MRI cell tracking can be used to monitor immune cells involved in the immunotherapy response, providing insight into the mechanism of action, temporal progression of tumour growth and individual potency of therapies. To evaluate whether MRI could be used to track immune cell populations in response to immunotherapy, CD8 
Introduction
Immunotherapies are one of the fastest growing classes of cancer therapies with the potential to rival traditional therapies as frontline cancer treatments (1) (2) (3) . Their rapid adoption has been driven by monoclonal antibodies (4) (5) (6) , checkpoint inhibitors (7) (8) (9) (10) (11) and/or cytokine treatments capable of eradicating tumours through manipulation of the immune system. Cancer vaccines (12) (13) (14) are another type of T cell based immunotherapy capable of activating the immune system that are currently in development and undergoing clinical testing.
Cancer progression is routinely monitored using imaging to assess traditional clinical outcomes such as tumour size. However, molecular imaging can also be a valuable research tool to explore and understand longitudinal molecular mechanisms initiated by novel cancer therapies both preclinically and clinically (15) (16) (17) (18) (19) (20) (21) (22) . A variety of imaging modalities (i.e. magnetic resonance imaging (MRI), positron emission tomography (PET), or fluorescence) have been used to investigate the effect of these therapies pre-clinically (15) (16) (17) (18) (19) (20) (21) (22) . Fluorescence or bioluminescence optical imaging is common in the context of monitoring intensity changes and migration of therapeutics conjugated to fluorescent tags or specific cell types genetically modified for bioluminescence. Both are used as reliable pre-clinical markers of interest (23) (24) (25) . However, optical imaging has limited tissue penetration depth and spatial resolution and lacks internal anatomy information provided by other imaging modalities such as MRI and PET/computed tomography (CT).
MRI has been extensively used preclinically to explore immunotherapy behaviour by tagging individual vaccine components with superparamagnetic iron oxide (SPIO), permitting longitudinal tracking of components over time (22) . MRI imaging can also be used to track specific cell populations labelled with SPIO (26) (27) (28) (29) (30) (31) . Previous research using MRI has achieved in vivo detection and visualization of single cells labelled with SPIO (32, 33) , which has been used to follow metastases originating from single cells visible by MRI (34) . MRI has also been used to track the migration of cells injected for direct therapeutic effect for various diseases, including dendritic and cytotoxic T cell injections used as cancer therapies (30, 31, (35) (36) (37) . However, rather than evaluate cellular migration patterns of a cellular therapy, we are tracking immune cells involved in the cancer immune response, providing insight on the mechanism of action, temporal progression and individual potency of immunotherapies.
Cytotoxic CD8
+ T cells (CTLs) are key cells in the fight against cancer (38) .
However, research has demonstrated that CTLs deployed directly as the sole cancer therapy have negligible therapeutic anti-tumour response for solid tumours (39) The success of cancer immunotherapies depends heavily on the interplay between cytotoxic and suppressive cell populations (41) . Monitoring the location and migration of these cells during tumour growth and/or following therapy can be critical for a successful immunotherapy approach. It facilitates an understanding of the mechanism of action as well as efficient assessment of dose levels, booster timing, and the introduction and interaction of additional treatments. The present study aims to achieve this using modern cell tracking with SPIO and MRI methods. The migration of CTLs has been extensively studied during cytotoxic T cell therapies (36, 45, 46) MDSC isolation and labelling. One day before cell injections, spleens were isolated from donor mice that also had tumours and had the same treatment as the recipient mice (either control or vaccine). MDSCs were purified from other splenocytes using a magnetic positive selection kit with anti-Gr-1 biotinylated antibody and a biotin specific MACS kit (MiltenyiBiotec). After isolation, cells were incubated overnight in cRPMI with 0.1 mg/mL of SPIO. 
MRI Image Analysis and Statistical Analysis. Volumetric segmentation was performed
by a single observer, and confirmed by a second independent reviewer. All images were first zero-padded (interpolated to a higher resolution grid to increase the effective resolution and image quality) using ImageJ (NIH). Images were analysed in RView for each mouse (53, 54) . A semi-automated region growing algorithm (54) 
The natural log of each histogram bin's signal value (I) is divided by the median signal value of the whole tumour ROI (I median Immunohistochemistry. All mice used for immunohistochemistry were terminated at 24
hours post-injection (separate group of mice from MRI). Transgenic C57BL/6 UbC-GFP mice were used as donor mice and normal C57BL/6 mice were used as recipients with tumour implants and vaccination done as described previously. Cryosectioning of tissues was performed at -20°C with 5 µm thickness. An hour after sectioning, the tissues were 
Results
Cell culture, labelling and purity. Cell purity was assessed by FACS before incubation with SPIO to ensure >80% purity. CTLs were >80% pure (Supporting (Fig. 3) . In untreated mice, cells were mostly concentrated at the tumour periphery. However, there were instances of cells localizing further centrally within the tumour (Fig 3; arrows) . In vaccinated mice, clusters of hypointensities were located both at the tumour periphery and in central regions. At 48 hours post-cell injections, hypointense regions disappeared from the tumour, which indicated that either cells are clearing from the tumour or that SPIO nanoparticles within the cells are undergoing degradation via the lysosomal pathway (58) . CTL recruitment to the LNs was visibly apparent 24h post cell injection (Fig. 6 ). (Fig. 8) , albeit one that was non-significant. CTLs were recruited to both tumour and vaccine draining inguinal LNs, particularly for vaccinated mice ( Fig. 7A and B ).
However the difference between vaccinated and control mice was not significant. Treg recruitment decreased to both inguinal LNs with vaccination ( Fig. 7C and D) . These data are consistent with previously published data using the cervical tumour model (12, 43, 61) .
We have clearly demonstrated that vaccination with the DPX-R9F formulation decreases the recruitment of suppressive cells types (MDSCs and Tregs) to the tumour and mildly increases the immune system's first line of defence: CTLs.
MRI immune cell tracking is a powerful technique for monitoring treatment efficacy due to its sensitivity in detecting individual variations in response to therapy. An increase in MDSC and Treg recruitment was evident 24h post-injection between vaccinated and untreated mice but also at an individual level, positively correlating tumour size to cellular recruitment within the tumour regardless of treatment (Fig. 8A, C) . These results were expected given that larger, more advanced stage tumours are more effective in recruiting suppressive immune cells (62) . This is likely one of the main reasons why vaccinated mice have significantly fewer Tregs and MDSCs. Additionally, previously published work (12, 61) has described that vaccination with DPX caused a significant decrease in MDSCs and Tregs in the spleen and blood of tumor bearing mice (measured using FACS) as well as within tumors (via immunohistochemistry).
The difference in CTL recruitment to the tumour was minimal for vaccinated mice compared to untreated mice at both time points (Fig. 8E) . The mean increase observed in Vaccination resulted in a large increase in CTL recruitment to both inguinal LNs.
Recruitment to the vaccine-draining LN (Fig. 7A ) was expected due to the vaccine-driven immune response (22) . In this response, the antigen presenting cells bring antigens from the vaccination site to the LNs for presentation to T cells like CTLs (22) . Increased recruitment in the tumour-draining LN ( Specificity and quantitation issues can be overcome by the use of fluorinated cellular labelling agents (29, (65) (66) (67) (68) . Previous studies have used fluorine cell labelling for several different cell types administered as an external cell-based therapy (i.e. dendritic cells (31, 65) , stem cells (67)) or to label macrophages to study inflammation (29) . Fluorine labelled cells can be detected with precise specificity using specialized surface coils or dual-tuned hydrogen/fluorine coils. Fluorine-based MRI cell tracking can also yield quantitative information (29, 67, 68) . Unfortunately, fluorine MRI is less sensitive than conventional proton MRI, making it difficult to detect smaller numbers of labelled cells, particularly at lower field strengths. It also requires more specialized equipment not necessarily available in all imaging facilities.
Quantitative information can also be obtained by using a pulse sequence like TurboSPI (69, 70) . Originally designed for imaging water in porous media that have long 
